Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 356

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial

Open access
Zein, Claudia O., Yerian, Lisa M., Gogate, Prema, Lopez, Rocio, Kirwan, John P., Feldstein, Ariel E., McCullough, Arthur J.·2011·Hepatology
DOI 10.1002/hep.24544
Open this paper in CoChat — free account

Abstract

The primary aim of this study was to compare the effects of pentoxifylline (PTX) versus placebo on the histological features of nonalcoholic steatohepatitis (NASH). In all, 55 adults with biopsy-confirmed NASH were randomized to receive PTX at a dose of 400 mg three times a day (n = 26) or placebo (n = 29) over 1 year. The primary efficacy endpoint was defined as improvement in histological features of NASH through reduction in steatosis, lobular inflammation, and/or hepatocellular ballooning as reflected by a decrease of ≥2 points in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS). After 1 year, intention-to-treat analysis showed a decrease of ≥2 points in the NAS in 38.5% of patients on PTX versus 13.8% of those on placebo (P = 0.036). Per protocol analysis, a decrease of ≥2 points in the NAS from baseline was observed in 50% of the patients on PTX versus 15.4% of those on placebo (P = 0.01). The mean change in NAS score from baseline was −1.6 in the PTX group, versus −0.1 in the placebo group (P < 0.001). PTX significantly improved steatosis (mean change in score −0.9 versus −0.04 with placebo, P < 0.001) and lobular inflammation (median change −1 versus 0 with placebo, P = 0.02). No significant effects in hepatocellular ballooning were observed. PTX also improved liver fibrosis (mean change in fibrosis score was −0.2 among those on PTX versus +0.4 among those on placebo, P = 0.038). Although not statistically significant (P = 0.17), improvement in fibrosis was observed in a greater proportion (35%) of patients in the PTX group compared to placebo (15%). Adverse effects were similar in both groups. Conclusion: PTX improved histological features of NASH compared to placebo. PTX was well tolerated in patients with NASH (ClinicalTrials.gov number NCT00590161). (Hepatology 2011)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.24544

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 34

  1. Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity., Hepatology, 40, 13871395, 10.1002/hep.20466 · DOI · Paper page
  2. Adams, 2005, The natural history of nonalcoholic fatty liver disease: a populationbased cohort study., Gastroenterolgy, 129, 113121, 10.1053/j.gastro.2005.04.014 · DOI · Paper page
  3. Bruix, 2001, Is bacterial ash the flash that ignites NASH?, Gut, 48, 148153
  4. Sanyal, 2001, Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities., Gastroenterology, 120, 11831192, 10.1053/gast.2001.23256 · DOI · Paper page
  5. Weltman, 1998, Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis., Hepatology, 27, 128133, 10.1002/hep.510270121 · DOI · Paper page
  6. Katsuki, 1998, Serum levels of tumor necrosis factoralpha are increased in obese patients with noninsulindependent diabetes mellitus., J Clin Endocrinol Metab, 83, 859862
  7. Tilg, 2000, Cytokines in alcoholic and nonalcoholic steatohepatitis., N Engl J Med, 343, 14671476, 10.1056/NEJM200011163432007 · DOI · Paper page
  8. Li, 2003, Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease., Hepatology, 37, 343350, 10.1053/jhep.2003.50048 · DOI · Paper page
  9. Koppe, 2004, Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet., J Hepatol, 41, 592598, 10.1016/j.jhep.2004.06.030 · DOI
  10. Ward, 1987, Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy., Drugs, 34, 5097
  11. Matzky, 1982, The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue., Arzneimittelforschung, 32, 13151318
  12. Koppe, 2004, Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet., J Hepatol, 41, 592598, 10.1016/j.jhep.2004.06.030 · DOI
  13. Hernandez, 2002, Pentoxifylline diminished acetaldehydeinduced collagen production in hepatic stellate cells by decreasing interleukin6 expression., Pharmacol Res, 46, 435443, 10.1016/S1043661802002025 · DOI
  14. Balibrea, 1994, Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages., Circ Shock, 43, 5156
  15. Abdel Salam, 2005, Effect of pentoxifylline on hepatic injury caused in the rat by the administration of carbon tetrachloride or acetaminophen., Pharmacol Rep, 57, 596603
  16. Kozaki, 1995, Effects of pentoxifylline pretreatment on Kupffer cells in rat liver transplantation., Hepatology, 21, 10791082, 10.1002/hep.1840210429 · DOI
  17. Romanelli, 1997, Effect of pentoxifylline on the degradation of procollagen type I produced by hepatic stellate cells in response to transforming growth factorbeta 1., Br J Pharmacol, 122, 10471054
  18. Preaux, 1997, Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblastlike cells., Hepatology, 26, 315322, 10.1002/hep.510260210 · DOI
  19. Raetsch, 2002, Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis., Gut, 50, 241247, 10.1136/gut.50.2.241 · DOI
  20. Adams, 2004, A pilot trial of pentoxifylline in nonalcoholic steatohepatitis., Am J Gastroenterol, 99, 23652368, 10.1111/j.1572-0241.2004.40064.x · DOI
  21. Satapathy, 2004, Beneficial effects of tumor necrosis factor inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis., Am J Gastroenterol, 99, 19461952, 10.1111/j.1572-0241.2004.40220.x · DOI
  22. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease., Hepatology, 41, 13131321, 10.1002/hep.20701 · DOI · Paper page
  23. Welch, 1990, Minimal model analysis of intravenous glucose tolerance testderived insulin sensitivity in diabetic subjects., J Clin Endocrinol Metab, 71, 15081518, 10.1210/jcem-71-6-1508 · DOI · Paper page
  24. Boston, 2003, MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test., Diabetes Technol Ther, 5, 10031015, 10.1089/152091503322641060 · DOI · Paper page
  25. Loo, 1998, Measurement of cell death., Methods Cell Biol, 57, 251264
  26. Feldstein, 2003, Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis., Gastroenterology, 125, 437443, 10.1016/S0016-5085(03)00907-7 · DOI · Paper page
  27. Miller, 2005, Metaanalysis: highdosage vitamin E supplementation may increase allcause mortality., Ann Intern Med, 142, 3746, 10.7326/0003-4819-142-1-200501040-00110 · DOI · Paper page
  28. CarterKent, 2008, Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment., Am J Gastroenterol, 103, 10361042
  29. Galluzi, 2009, Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes., Cell Death Differ, 16, 10931107
  30. Sekut, 1995, Antiinflammatory activity of phosphodiesterase (PDE)IV inhibitors in acute and chronic models of inflammation., Clin Exp Immunol, 100, 126132
  31. Vircheva, 2010, In vivo effects of pentoxifylline on enzyme and nonenzyme antioxidant levels in rat liver after carrageenaninduced paw inflammation., Cell Biochem Funct, 28, 668672, 10.1002/cbf.1705 · DOI
  32. Berman, 1990, Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoe skin and their production of collagen, glycosaminoglycans and fibronectin., Br J Dermatol, 123, 339346, 10.1111/j.1365-2133.1990.tb06294.x · DOI
  33. Duncan, 1995, Pentoxifylline, pentifylline, and interferons decrease type I and type III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor I downregulation., J Invest Dermatol, 104, 282286, 10.1111/1523-1747.ep12612819 · DOI
  34. Modi, 2010, Increased caffeine consumption is associated with reduced hepatic fibrosis., Hepatology, 51, 201209, 10.1002/hep.23279 · DOI · Paper page

Cited by

See all 356

Metadata

Authors
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-11
Volume
54
Issue
5
Pages
1610-1619
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.24544
OpenAlex
W2116393673
Cited by
356
References
7
FWCI
18.59
Type
journal article
Language
en
Open access
green
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1400 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. https://app.cochat.ai/papers/10.1002/hep.24544
The paper
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011). Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology. https://doi.org/10.1002/hep.24544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.